Please assess the completion status of the following clinical trial:

Trial Title: Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients referred for ERCP at the University of Alberta~* Age greater than 18 years~* Ability to provide written informed consent~Exclusion Criteria:~* Acute pancreatitis~* Active peptic ulcer disease~* Rectal disease~* Aspirin-induced asthma~* Nonsteroidal anti-inflammatory drug (NSAIDs) induced hypersensitivity~* Pregnancy~* Breast feeding~* Creatinine clearance \< 30 ml/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rectal Indomethacin pre-ERCP (Type: ACTIVE_COMPARATOR): Patients will receive rectal indomethacin 100mg 30 minutes before procedure (ERCP).
- Rectal Indomethacin post-ERCP (Type: ACTIVE_COMPARATOR): Patients will receive rectal indomethacin 100mg immediately after procedure (ERCP)

Based on this trial design, predict the completion outcome and termination type (if applicable).